|
 |
|
|||||||
|
|||||||||
© 2002 by the American Diabetes Association, Inc.
Letters: Observations |
Postischemic Microcirculatory Blood Flow Correlates Negatively and Independently With Plasma C-Reactive Protein in Longstanding Type 1 Diabetes
1 St. Thomas’ Hospital, London, U.K.
2 Queen Alexandra Hospital, Portsmouth, U.K.
3 University Department of Medicine, University of Western Australia, Royal Perth Hospital, Perth, Australia
Moderately increased plasma C-reactive protein (CRP), an acute phase protein produced by the liver and an exquisitely sensitive marker of inflammation, is associated with an increased risk of cardiovascular disease (1). It is not known how systemic inflammation leads to atherosclerosis, but experimental (2) and clinical (3) studies have suggested that it may do so by causing endothelial dysfunction, a process central to the development of atherosclerosis.
Reactive hyperemia (RH) is an endothelium-dependent, physiological, and probably protective response to tissue ischemia that is reduced in patients with atherosclerosis or risk factors for atherosclerosis. The forearm vascular bed, which is readily accessible and rarely affected by atheromatous change, is a useful site to study RH using noninvasive techniques. A close relationship has been shown between coronary endothelial function and RH in the human forearm (4).
To further investigate the relationship between inflammation and endothelial dysfunction, we have studied RH and circulating CRP in 50 subjects (28 men), all of whom had type 1 diabetes for at least 25 years. Urinary albumin/creatinine ratio (ACR), total and HDL cholesterol, and HbA1c were all measured as previously described (5). CRP was measured by enzyme-linked immunosorbent assay (ELISA) (within-assay coefficient of variation 8%). Forearm RH was measured using the method of Tagawa et al. (6).
The patients had a mean age of 47 ± 2 years and a mean BMI of 27 ± 1 kg/m2. Mean total and HDL cholesterol were 5.5 ± 0.2 and 1.4 ± 0.1 mmol/l, respectively. Mean systolic and diastolic blood pressure were 136 ± 3 and 75 ± 2 mmHg, respectively. Eight patients had microalbuminuria (ACR >3 mg/mmol), and three had established nephropathy (urinary albumin excretion rate >300 mg/24 h).
Mean baseline forearm bloodflow (FBF) was 2.8 ± 0.2 ml · 100 ml-1 · min-1 and did not correlate with any measured variable. Mean peak FBF was 7.6 ± 0.5 ml · 100 ml-1 · min-1. Peak FBF was higher in men and correlated negatively with BMI (r = -0.31, P < 0.05) and log CRP (r = -0.38, P < 0.02). To determine whether the relationship between CRP and RH was independent of other variables, stepwise linear regression analysis was performed. Possible predictor variables were entered into the model if a significant bivariate relationship was observed between the measure of RH and the predictor variable. This analysis revealed CRP to be the only independent predictor of peak bloodflow (ß = -0.135, P < 0.02). The findings were not altered when patients with microalbuminuria or nephropathy were excluded from analysis.
Although the cross-sectional nature of this study does not permit a cause-effect relationship to be determined, the negative relationship between RH and CRP is consistent with the hypothesis that inflammation contributes to endothelial dysfunction in diabetic patients. Schalwijk et al. (7) recently studied CRP in a similar population of long-standing type 1 diabetic subjects and demonstrated increased CRP as compared with a well-matched control population. By assessing the glycation pattern of 
-1-acid glycoprotein, they demonstrated that this effect represented a chronic rather than acute hepatic inflammatory response. Furthermore, in concordance with our findings, they also demonstrated an inverse relationship between CRP and plasma markers of endothelial function.
These observations have potentially important therapeutic implications. Data from the Cholesterol and Recurrent Events (CARE) study have demonstrated that hydroxymethylglutaryl (HMG) CoA reductase inhibitors reduce CRP independently of their effects on plasma lipids (8). It is conceivable that these or other agents, which reduce CRP, might improve endothelial function and reduce development of vascular disease in diabetes.
In summary, CRP correlates negatively and independently with forearm RH in patients with longstanding type 1 diabetes. Prospective studies are warranted to determine whether inflammation precedes endothelial dysfunction and whether therapeutic strategies that reduce inflammation would also reduce development of vascular disease in diabetes.
Footnotes
Address correspondence to Dr. James Gibney, Pituitary Research Unit, Garvan Institute of Medical Research, 384 Victoria St., Darlinghurst, Australia. E-mail: j.gibney{at}garvan.unsw.edu.au.
References
-
Ridker PM, et al: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973–979, 1997
[Abstract/Free Full Text]
-
Vane JR, Anggard EE, Botting RM: Regulatory functions of the vascular endothelium. N Engl J Med 323:27–36, 1990[Medline]
-
Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM: Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 102:1000–1006, 2000
[Abstract/Free Full Text]
-
Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, Lieberman EH, Ganz P, Creager MA, Yeung AC, et al: Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 26:1235–1241, 1995[Abstract]
-
Powrie JK, Watts GF, Ingham JN, Taub NA, Talmud PJ, Shaw KM: Role of glycaemic control in development of microalbuminuria in patients with insulin dependent diabetes. BMJ 309:1608– 1612, 1994
[Abstract/Free Full Text]
-
Tagawa T, Imaizumi T, Endo T, Shiramoto M, Harasawa Y, Takeshita A: Role of nitric oxide in reactive hyperemia in human forearm vessels. Circulation 90:2285–22890, 1994
[Abstract/Free Full Text]
-
Schalkwijk CG, Poland DC, van Dijk W, Kok A, Emeis JJ, Drager AM, Doni A, van Hinsbergh VW, Stehouwer CD: Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 42:351–357, 1999[Medline]
-
Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E: Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100:230–235, 1999
[Abstract/Free Full Text]
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |